Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Sun Pharmaceutical Industries Ltd.
Change Company   
BSE Code 524715
ISIN Demat INE044A01036
Book Value 104.58
NSE Code SUNPHARMA
Dividend Yield % 1.01
Market Cap 3799346.92
P/E 79.18
EPS 20.00
Face Value 1  
04-Aug-2025 Sun Pharmaceutical Industries informs about discl...
01-Aug-2025 Clarification sought from Sun Pharmaceutical Ind...
31-Jul-2025 Sun Pharmaceutical Industries reports 20% fall in...
21-Jul-2025 Sun Pharmaceutical Industries informs about pres...
18-Jul-2025 Sun Pharma incorporates subsidiary company in Chi...
15-Jul-2025 Sun Pharmaceutical Industries launches LEQSELVI i...
15-Jul-2025 Sun Pharmaceutical Industries gains on launching ...
14-Jul-2025 Sun Pharma Advanced Research Company informs abou...
25-Jun-2025 Sun Pharma’s partner withdraws application for ma...
25-Jun-2025 Sun Pharmaceutical Industries informs about inve...
25-Jun-2025 Sun Pharma gains on the BSE
14-Jun-2025 USFDA conducts GMP inspection of Sun Pharma’s Hal...
26-May-2025 Sun Pharmaceutical Industries to invest up to $25...
23-May-2025 Sun Pharmaceutical Industries reports 19% fall in...
24-Apr-2025 Sun Pharmaceutical Industries informs about press...
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.